Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment

Wang, Wenyu; Han, Youngjin; Jo, Hyun A.; Lee, Juwon; Song, Yong Sang

doi:10.1186/s13045-020-00893-3

Cited by 52 publications

(40 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cancer is a highly heterogeneous disease and the biological features and behaviors of cancers are largely dependent on the tumor microenvironment [ 42 ]. The different regulatory roles of SIRT2 in drug response might be due in part to the different substrates and downstream pathways.…”

Section: Discussionmentioning

confidence: 99%

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

Wang

Kim

et al. 2020

Antioxidants

Self Cite

View full text Add to dashboard Cite

Cisplatin resistance remains a significant obstacle for improving the clinical outcome of ovarian cancer patients. Recent studies have demonstrated that cisplatin is an important inducer of intracellullar reactive oxygen species (ROS), triggering cancer cell death. Sirtuin 2 (SIRT2), a member of class III NAD+ dependent histone deacetylases (HDACs), has been reported to be involved in regulating cancer hallmarks including drug response. In this study, we aimed to identify the role of SIRT2 in oxidative stress and cisplatin response in cancer. Two ovarian cancer cell lines featuring different sensitivities to cisplatin were used in this study. We found different expression patterns of SIRT2 in cisplatin-sensitive (A2780/S) and cisplatin-resistant (A2780/CP) cancer cells with cisplatin treatment, where SIRT2 expression was augmented only in A2780/S cells. Furthermore, cisplatin-induced ROS generation was responsible for the upregulation of SIRT2 in A2780/S cells, whereas overexpression of SIRT2 significantly enhanced the sensitivity of cisplatin-resistant counterpart cells to cisplatin. Our study proposes that targeting SIRT2 may provide new strategies to potentiate platinum-based chemotherapy in ovarian cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

Wang

Kim

et al. 2020

Antioxidants

Self Cite

View full text Add to dashboard Cite

show abstract

“…MicroRNAs (miRNAs) are a part of non-coding single-stranded small RNAs (18-22 nucleotides) that can suppress gene expression through binding the 3'-UTR of target mRNA [8]. With the further understanding of miRNAs, researchers find miRNAs can function as oncogenes or tumor suppressors to modulate tumor cell proliferation, apoptosis, immune response, and reshape microenvronment [9][10][11][12]. Recently, a growing number of studies report miRNAs play a pivotal role in regulating the EMT program and the CSCs genesis [13].…”

Section: Introductionmentioning

confidence: 99%

MiRNA-mediated EMT and CSCs in cancer chemoresistance

Dong

Zhu

et al. 2021

Exp Hematol Oncol

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are a small group of cancer cells, which contribute to tumorigenesis and cancer progression. Cancer cells undergoing epithelial-to-mesenchymal transition (EMT) acquire the chemoresistant ability, which is regarded as an important feature of CSCs. Thus, there emerges an opinion that the generation of CSCs is considered to be driven by EMT. In this complex process, microRNAs (miRNAs) are found to play a key role. In order to overcome the drug resistance, inhibiting EMT as well as CSCs phenotype seem feasible. Thereinto, regulating the EMT- or CSCs-associated miRNAs is a crucial approach. Herein, we conduct this review to elaborate on the complicated interplay between EMT and CSCs in cancer chemoresistance, which is modulated by miRNAs. In addition, we elucidate the therapeutic strategy to overcome drug resistance through targeting EMT and CSCs.

show abstract

“…established a new plasmid delivery system, Micropoly-transfecter, which can deliver circ-1073 plasmid through intratumoral injection, thereby inhibiting tumor progression [ 120 ]. Moreover, accumulating evidence has indicated the potential value of exosomal circRNAs in clinical application [ 121 ]. Exosomes could carry circ-0051443 from normal cells to HCC cells, and inhibit the malignant biological behaviors through inducing apoptosis and cell cycle arrest [ 122 ].…”

Section: Potential Clinical Application Of Circrnasmentioning

confidence: 99%

The functions and clinical significance of circRNAs in hematological malignancies

et al. 2020

View full text Add to dashboard Cite

With covalently closed circular structures, circular RNAs (circRNAs) were once misinterpreted as by-products of mRNA splicing. Being abundant, stable, highly conserved, and tissue-specific, circRNAs are recently identified as a type of regulatory RNAs. CircRNAs bind to certain miRNAs or proteins to participate in gene transcription and translation. Emerging evidence has indicated that the dysregulation of circRNAs is closely linked to the tumorigenesis and treatment response of hematological malignancies. CircRNAs play critical roles in various biological processes, including tumorigenesis, drug resistance, tumor metabolism, autophagy, pyroptosis, and ferroptosis. The N6-methyladenosine modification of circRNAs and discovery of fusion-circRNAs provide novel insights into the functions of circRNAs. Targeting circRNAs in hematological malignancies will be an attractive treatment strategy. In this review, we systematically summarize recent advances toward the novel functions and molecular mechanisms of circRNAs in hematological malignancies, and highlight the potential clinical applications of circRNAs as novel biomarkers and therapeutic targets for future exploration.

show abstract

Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment

Cited by 52 publications

References 127 publications

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer

MiRNA-mediated EMT and CSCs in cancer chemoresistance

The functions and clinical significance of circRNAs in hematological malignancies

Contact Info

Product

Resources

About